Alzheimers Resource for care and treatment of Alzheimers and alzheimers symptoms
Alzheimers Resource & Support - 1,500+ Alzheimers Articles & Abstracts
AlzheimerSupport.com, Alzheimers, Alzheimer's, Alzheimer's Disease, Alzheimers Disease, alzheimers symptom, alzheimers treatment, dementia, acetylcholinesterase, AChE, Huperzine A, SEROQUEL, Quetiapine, Reminyl, galantamine, Statin drugs, statin, Namenda, Memantine,
Welcome to the AlzheimerSupport.com Website!
ProHealth’s AlzheimerSupport.com is your home for Alzheimers news, support, and comprehensive nutritional solutions. We attract over 5 million visitors a year because we are a patient owned company that understands your needs, and our goal is to empower you to take control of your health.
Patient Owned
The ProHealth story begins back in August 1981, when at the age of 23, Rich Carson woke up one day with severe flu-like symptoms. Rich saw a specialist who ran tests for strep throat and mononucleosis, but the results for both tests were negative. Sometime later, while still feeling extremely ill, Rich spoke with an internist who informed him that he may be suffering from either a chronic cytomegalovirus or a chronic Epstein-Barr virus infection. Pointed in the right direction, Rich telephoned every researcher he could find to investigate his illness, which has since come to be known as Chronic Fatigue Syndrome.
By 1986, Rich was spending two or three hours a day on the telephone with CFS patients and researchers, and started one of the first and largest CFS support groups in the country. Rich’s determination to help CFS patients soon lead to the creation of ProHealth, Inc. Founded in 1988, the company’s mission is to provide a comprehensive resource for people with Chronic Fatigue Syndrome and Fibromyalgia.
An important part of Rich’s treatment plan includes alternative therapies that greatly relieve many of his symptoms. The Health Resource Catalog was published to share with other patients the supplements he found to be most effective. Additionally, Rich realized the Internet is a great way to spread useful, up-to-the-minute information to the many thousands of CFS and FM sufferers worldwide, and so ImmuneSupport.com was created.
Commerce with Compassion
ProHealth knows that research is the key to finding cures for CFS and FM, and it is our mission to help fund important research studies. Since 1988, ProHealth has raised and donated over $2.3 million to organizations dedicated to researching CFS and FM and finding effective treatments. We have proudly made contributions to Action for ME, the CFIDS Association of America, Inc., the National Fibromyalgia Association (NFA), and the National Fibromyalgia Research Association, to name a few. When you shop with ProHealth you support research, since a portion of the profits from each purchase you make goes toward funding CFS and FM research and advocacy.
“This is not a commercial venture that will contribute to personal wealth, but a way to support those who have this terrible illness. It exists for the benefit of patients, with more than half of our profits dedicated to research and advocacy, a track record I believe is unsurpassed in private industry.” – Rich Carson
Your Health Resource
AlzheimerSupport.com brings you daily research and treatment news, exclusive interviews with leading physicians, traditional and alternative treatment options, and symptom control advice. AlzheimerSupport.com continually grows its information library to keep you informed of all your options, and help you successfully manage your most troubling symptoms and cope with the many issues you face.
From our free weekly Treatment & Research bulletins, advocacy event postings, support group listings, doctor directories, and over 300 nutritional supplements and specialty formulas, AlzheimerSupport.com is dedicated to serving you in your quest for better health and wellbeing.
Traumatic Brain Injury Hastens Onset of Alzheimer's Disease
Familial Alzheimer's disease: Genetic influences on the disease process
Plaque, the hallmark of Alzheimer's disease is revealed in three dimensions
Study Furthers Understanding of Critical Alzheimer's Disease Gene
Genetic Factors
Alzheimer's Disease Begins Before Symptoms Appear
Research Provides Further Support for Lifelong Influences on Brain and Cognitive Health
Diagnosis and management of Alzheimer disease.
Consulting the Doctor
Getting the Right Care
ApoE Testing in Alzheimer's Disease
Anxiety of Alzheimer's disease: prevalence, and comorbidity.
Alterations in immune functions during normal aging and Alzheimer's disease.
Pain threshold and tolerance in Alzheimer's disease.
Alzheimer protein found critical to brain development
Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.
Psychosis in Alzheimer's Disease.
Mayo Clinic study identifies brain changes in people likely to develop Alzheimer's disease
Clinical Aspects of Alzheimer's Disease
Nutrition and aging
Exercise and activity level in Alzheimer's disease: a potential treatment focus.
Pharmacologic management of Alzheimer disease, Part I: Hormonal and emerging investigational drug therapies.
Therapy and Prevention
Slowing Alzheimer's Disease: Blueberries, New Thrills for Those Over the Hill
Alzheimer's Disease & Ginkgo Biloba
Mortality Trends for Alzheimer's Disease
Towards a Better Understanding of Alzheimers Disease
The Impact of Alzheimer's Disease
A Look at the Future
Mortality from Alzheimer's disease: an update.
Behavioral and Social Aspects of Alzheimers Disease
Special Care Units for AD
Cost of Alzheimer's disease and related dementia in managed-medicare.
Potential cost savings in residential care for Alzheimer's disease patients.
Alzheimer Treatment
Ginkgo Proven to be an Effective Alzheimer's Treatment
Researchers investigated Alzheimer's treatment drugs to test their efficacy opposed to treatment with Ginkgo extract. Study results show that there is not a significant difference between receiving treatment using a drug or treatment using Ginkgo extract. Researchers concluded by noting that Ginkgo extract should be considered equally effective in the treatment of mild to moderate Alzheimer's dementia.
Effective Alzheimer's Treatment with Minimal Side-Effects
The benefits of taking acetylcholinesterase (AChE) inhibitors for Alzheimer's disease is well known and clinically proven. Huperzine A is a drug free AChE inhibitor. AChE inhibitors have the potential to delay the decline in cognitive and mental functions in Alzheimer patients. The multiple benefits Alzheimer patients experience as a result of including AChE inhibitors in their treatment program make them an excellent Alzheimer's treatment.
Future Alzheimer's Treatment: Nueral Stem Cells
All cells start out as stem cells and go on to become specialized cells, this new method is revolutionary since it is able to direct stem cells to become specific types of cells in order to replace diseased cells. The transplantation of CNS stem cells to replace damaged or diseased nerve tissue and restore neural function is widely regarded as a promising new approach to Alzheimer’s disease treatment.
New Treatment Could Help Prevent Alzheimer's
Researchers have succeeded for the first time in designing a chemical that can stop the chain reaction that leads to Alzheimer's disease. This treatment differs from other Alzheimer's research because it prevents the beginnings of the disease rather than treating the symptoms or coping with the damaged cells.
Huperzine A: Potential Therapeutic Agent for Alzheimer’s Disease
Huperzine A has been proven to have a powerful and lasting effect on the brain while keeping side effects to a minimum. In addition, recent news reports Huperzine A can lower neuronal cell death attributed to glutamate. The multiple benefits of Huperzine A (and minimal side-effects) make it a promising Alzheimer’s treatment.
New Drug Program Helps More Than 100,000 Patients in First Three Weeks
A new program that helps patients in need get prescription medicines is generating an outpouring of inquiries from patients nationwide.
04/01/05 FDA MedWatch: Reminyl (galantamine) Precautions Due to Deaths Reported in Clinical Trials
Ortho-McNeil Neurologics modified the PRECAUTIONS section of the Prescribing Information for Reminyl, approved only for the treatment of mild to moderate Alzheimer's Disease. The changes provide new safety information regarding the results of two randomized, placebo-controlled trials of 2 years duration in subjects with mild cognitive impairment(MCI).
02/24/05 Quetiapine speeds up rate of decline in Alzheimers?
Quetiapine, a drug commonly used in nursing homes to treat agitation and related symptoms in people with Alzheimers' disease actually worsens patients' illness, speeding up their rate of decline significantly, says a paper published on bmj.com.
11/08/04 New Compounds Effective Against Alzheimer's Disease Onset and Progression
Drug discovery researchers at Northwestern University have developed a new class of compounds that have the potential to reduce the inflammation of brain cells and the neuron loss associated with Alzheimer's disease.
11/02/04 Jefferson Neuroscientists Studying New Type of Alzheimer’s Drug Aimed at Halting Disease Progression
Researchers hope Alzhemed will prove effective in international clinical trial.
08/05/04 Merck Signs Deals In Oncology And Alzheimer's
Merck and Celera Diagnostics have begun to collaborate to find drug targets and biomarkers for Alzheimer’s disease.
07/29/04 Celera, Merck to Tackle Alzheimer's
Celera Genomics has signed its third big research partnership this month. The company says Merck will help fund research into potential treatments for Alzheimer's disease based of Celera's gene discoveries.
07/23/04 Two Alzheimer's Drugs Show Potential - U.S. Studies
Two experimental Alzheimer's drugs have the potential to prevent or halt the progress of the brain-wasting disease, doctors said on Wednesday, July 21, 2004.
07/22/04 Study Examines SEROQUEL for the Treatment of Agitation in Elderly Patients with Dementia
Study Results Suggest SEROQUEL May Reduce Symptoms of Agitation Associated With Dementia in Long-Term Care Patients; Analysis Shows No Evidence of an Increased Risk of Cerebrovascular Adverse Events.
07/19/04 No Clear-Cut Answers on Statins as Therapy for Alzheimer's Disease
Statins continue to generate interest as a possible preventive strategy for Alzheimer's disease, based on studies at The 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD), presented by the Alzheimer's Association.
Ceregene Confirms Plans to Further Develop Alzheimer's Disease Gene Therapy
Ceregene, Inc., today announced that based on preliminary findings in a study conducted at the University of California, San Diego (UCSD), it will advance its gene therapy for Alzheimer's disease into further clinical development.
04/28/04 Large New Study Supports Statins For Alzheimer's Disease
A large new study has found strong further evidence that statin drugs have therapeutic benefit for Alzheimer's Disease (AD). Statin drugs are widely used cholesterol-lowering drugs. Researchers from France presented these significant new findings at the American Academy of Neurology meeting this week in San Francisco.
04/15/04 New Study Results Show Benefit for Alzheimer's Disease Patients Taking Lipitor(TM)
Results of a Sun City, Arizona research study unveiled today in Montreal showed that Lipitor(TM), a cholesterol-lowering medication, slows the progression and reduces the deterioration of Alzheimer's Disease (AD).
04/14/04 Neurochem Reports Positive Alzheimer's Trial Data
Neurochem Inc. reported positive data on Wednesday [4/14/04] for its drug to treat Alzheimer's and said it expects Alzhemed to start phase III trials in June.
04/08/04 Alzheimer's Drugs Frustrate Doctors
The drugs now available to treat the memory and thinking problems of Alzheimer's patients have failed to live up to the public's high expectations and offer such modest benefits that many doctors have doubts about prescribing them.
04/01/04 Statin Drugs Reduce Alzheimer's Risk According to Studies: Nymox
"Statins are safe and well tolerated," said Dr. Michael Munzar, Medical Director of Nymox Pharmaceutical Corporation. "A very strong case is growing for their expanded use in AD."
02/23/04 Namenda(TM) Shows Benefit in Behavioral Disturbances Associated With Moderate to Severe Alzheimer's Disease
Forest Laboratories, Inc. announced today the presentation of new data on behavioral outcomes from the first clinical trial evaluating the treatment of patients with moderate to severe Alzheimer's disease with a combination of two available Alzheimer's drugs: Namenda(TM) (memantine HCl) and donepezil
12/22/03 Clinical Trial of Alzheimer's Disease Drug Shows Clear Reductions in AD Development
A new clinical trial has shown that a treatment for Alzheimer's disease slowed the progression of cognitive decline in a group of patients with moderate to severe symptoms. The findings of the trials into the effectiveness of the drug Clioquinol on the treatment of AD, were carried out by University College of London's Department of Psychiatry and Behavioural Sciences and Prana Biotechnology Limited.
10/17/03 FDA Approves Alzheimer's Drug: Memantine
Memantine is first prescription drug approved for late stages of Alzheimer's disease.
09/25/03 FDA Backs New Alzheimer’s Drug: Memantine
A drug long used in Germany to ease the ravages of Alzheimer’s disease took a step toward the U.S. market on Wednesday when government scientists backed memantine as the first treatment specifically for late stages of the mind-stealing disease.
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I